Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
2.190
0.00 (0.00%)
Jun 29, 2026, 10:20 AM EDT - Market open
Company Description
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States.
It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Rα in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
The company was founded in 2012 and is headquartered in San Diego, California.
Connect Biopharma Holdings Limited
| Country | United States |
| Founded | 2012 |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Barry Quart |
Contact Details
Address: 3580 Carmel Mountain Road, Suite 200 San Diego, California 92130 United States | |
| Phone | 877 245 2787 |
| Website | connectbiopharm.com |
Stock Details
| Ticker Symbol | CNTB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001835268 |
| CUSIP Number | G23549101 |
| ISIN Number | KYG235491019 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David L. Szekeres J.D. | President |
| Lisa Peraza CPA | Senior Vice President of Finance |
| Jeff Cohn J.D. | General Counsel and Corporate Secretary |
| Sean T. Ristine | Vice President of Human Resources |
| Dr. Lei Sun Ph.D. | Vice President of Biologics and Head of CMC |
| Dr. Srikanth Pendyala M.D. | Senior Vice President of Clinical Development(Consultant) |
| Kimberly J. Manhard | Executive Vice President and Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 1, 2026 | EFFECT | Notice of Effectiveness |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | F-3 | Filing |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| Apr 23, 2026 | 8-K | Current Report |
| Apr 14, 2026 | SCHEDULE 13G | Filing |
| Apr 1, 2026 | SCHEDULE 13D/A | Filing |
| Mar 31, 2026 | 10-K | Annual Report |
| Mar 31, 2026 | 8-K | Current Report |